Cardiovascular Disease

Heating Up: Two Heart Medications May Increase Risk

hot

Antiplatelet medications and beta blockers can improve survival and quality of life for people with cardiovascular disease. But those protections may come with added risk on hot summer days.

A study published in Science found that a disproportionate number of people who suffer non-fatal heart attacks during hot weather are taking antiplatelet or beta blocker medications. 

Researchers analyzed 2.5k cases in which a non-fatal heart attack occurred during hot weather. Heat-associated MI events were more common among those taking the heart drugs:

  • Antiplatelet medication users had a 63% increased risk.
  • Beta-blocker users had a 65% increased risk.
  • People taking both drugs had a 75% higher risk.
  • Non-users were not more likely to have a heart attack on hot days. 

Importantly, the authors do not claim that these medications cause heart attacks, noting that patients who take these prescriptions are likely doing so because they are more susceptible to cardiac events.  

Even so, a clue indicates that the heart drugs may indeed be partly to blame. Younger patients (25 to 59 years) had lower rates of coronary heart disease than older participants (60 to 74 years), yet younger patients taking beta-blockers and antiplatelet medications were still more susceptible to heat-related heart attacks.

The authors speculate that the medications may make it harder for people to regulate their body temperature, but future research will be necessary to investigate this. 

The Takeaway

Two groups of heart medications – beta blockers and antiplatelets – could potentially place patients at a higher risk of heat-related heart attacks. As temperatures continue to creep up globally, the risk associated with these medications may become even more pronounced. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!